Compare Uber Technologies Inc (UBER) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uber Technologies Inc vs Viatris Inc — how do they compare? Uber Technologies Inc trades at $71.61 (market cap $149.37B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Uber Technologies Inc is far larger — about 7.8× Viatris Inc's market cap, and Viatris Inc pays a 2.89% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| UBER | VTRS | |
|---|---|---|
Market Cap | $149.37B | $19.09B |
Sector | Industrials | Health |
52-Week High | $100.10 | $17.86 |
52-Week Low | $65.94 | $9.49 |
Enterprise Value | $158.71B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uber's stock trades at $71.08, down 6.18% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $52.02B in 2025 with a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Spain and Germany, alongside cost-cutting measures like HR layoffs and AI spending caps.
The outlook is mixed: robust revenue growth and a dominant market position support upside, but competitive pressures, regulatory risks, and a projected negative cash flow in 2026 pose challenges. Analyst consensus is strongly bullish with a $102.56 price target, suggesting significant potential if execution aligns with autonomous vehicle initiatives.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
